Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
|Articles|October 14, 2011
GMP Labs Earns Health Canada Reference Number
The company's foreign site reference number allows for numerous advantages in dealing with the Canadian market for natural health products.
Advertisement
GMP Labs Inc. (Anaheim, CA) has successfully petitioned for a foreign site reference number from Health Canada. GMP Labs says the reference number gives the company the following advantages:
- Elimination of the need for GMP Labs to submit the same or similar Good Manufacturing Practices (GMP) information to multiple Canadian importers.
- Elimination of the need for Health Canada to review GMP evidence for the company submitted by multiple Canadian importers.
- Increased efficiency in assessment of the company’s license applications
- Ability for foreign manufacturers, packagers, and labels of natural health products to submit information regarding GMP compliance directly to health Canada.
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
2
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
3
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
4
Lonza Capsugel to Feature Organicaps, UC-II, and Capsule Delivery Technologies at SupplySide Global 2026
5